Literature DB >> 12745749

The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients.

Caner Cavdar1, Murat Sayan, Aykut Sifil, Cigdem Artuk, Nezihe Yilmaz, Hakki Bahar, Taner Camsari.   

Abstract

BACKGROUND: The immune system in renal transplant (Tx), Continuous Ambulatory Peritoneal Dialysis (CAPD) and hemodialysis (HD) patients have been suppressed and antibody response to vaccination is weaker than that of the normal population. Additionally immune response to vaccination also differs from each other in aforementioned three groups resulting from different levels immunosuppression. In the present study, detection of antibody response to influenza vaccine as an indicator of the level of immunity in Tx, CAPD and HD patients was aimed PATIENTS AND METHODS: Forty-eight patients (17 Tx, 16 CAPD and 15 HD) and 10 healthy adults, as a control group were enrolled into the study. Purified, split-virus, commercial trivalent influenza vaccine (VAXIGRIP--Pasteur Merieux Connaught, single dose of 0.5 ml into the deltoid muscle) containing 15 microg of each hemagglutinin of A/Johannesburg/82/96 (H1N1), A/Nachang/933/95 (H3N2) and B/Harbin/07/94 (B) strains were administered to all subjects. Serum samples were collected before and 1 month after vaccination to determine antibody titers. Hemagglutination-inhibition test (HI) was applied for determination of antibody response. The antibody response against each strain was measured separately. In addition to measurement of antibody response, increments in antibody titer (n-fold increase in titer), proportion of patients with protective antibody levels and seroconversion levels were taken into account. Wilcoxon paired 2 test and Mann-Whitney U test were applied for statistical analysis. p < 0.05 was accepted as significance level.
RESULTS: Significant increases in antibody titers for all three antigens were observed in the study groups after vaccination (p = 0.001). However, the increase in titer of H3N2 was lower in Tx, CAPD and HD patients than that of the control group (1.0-2.0 vs 5.00) (p = 0.01). The proportion of protective antibody titers and seroconvertions were increased after vaccination in all subjects. Proportions of patients with protective antibody titers after vaccination were lower in Tx, CAPD and HD groups in comparison to control group.
CONCLUSION: Although antibody titers in Tx, CAPD and HD patients presented significant increases after vaccination, the proportions of patients with protective antibody titers were lower in comparison to control group. Tx, CAPD and HD patients should be vaccinated every year to be able avoid potential morbidity and mortality of the influenza infection. Trial of high dose vaccination protocols may be useful to increase the proportion of patients with protective antibody levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745749     DOI: 10.1080/00365590310008749

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  27 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

2.  Sepsis and AKI: more complex than just a simple question of chicken and egg.

Authors:  P M Honoré; R Jacobs; W Boer; O Joannes-Boyau
Journal:  Intensive Care Med       Date:  2010-12-09       Impact factor: 17.440

Review 3.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

4.  Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD.

Authors:  Delphine R Nelson; Alicia M Neu; Alison Abraham; Sandra Amaral; Donald Batisky; Jeffrey J Fadrowski
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-07       Impact factor: 8.237

5.  Determinants of influenza vaccination among solid organ transplant recipients attending Sicilian reference center.

Authors:  Vincenzo Restivo; Giovanni Vizzini; Alessandra Mularoni; Cinzia Di Benedetto; Santi Mauro Gioè; Francesco Vitale
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

6.  Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients.

Authors:  Jungmin Son; Soo Bong Lee; Dong Won Lee; Il Young Kim; Su Jin Lee; Sun Min Lee; Sang Heon Song; Eun Young Seong; Ihm Soo Kwak
Journal:  Clin Exp Nephrol       Date:  2012-09-19       Impact factor: 2.801

7.  Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population.

Authors:  David T Gilbertson; Kenneth J Rothman; Glenn M Chertow; Brian D Bradbury; M Alan Brookhart; Jiannong Liu; Wolfgang C Winkelmayer; Til Stürmer; Keri L Monda; Charles A Herzog; Akhtar Ashfaq; Allan J Collins; James B Wetmore
Journal:  J Am Soc Nephrol       Date:  2019-01-24       Impact factor: 10.121

8.  Beneficial in vitro effect of N-acetyl-cysteine on oxidative stress and apoptosis.

Authors:  Jacek Zachwieja; Marcin Zaniew; Waldemar Bobkowski; Ewa Stefaniak; Alfred Warzywoda; Danuta Ostalska-Nowicka; Agnieszka Dobrowolska-Zachwieja; Maria Lewandowska-Stachowiak; Aldona Siwińska
Journal:  Pediatr Nephrol       Date:  2005-04-05       Impact factor: 3.714

9.  Seasonal maintenance of influenza vaccine-induced antibody response in kidney transplant recipients.

Authors:  Kelly A Birdwell; Mine R Ikizler; Li Wang; Daniel W Byrne; Edith C Sannella; Peter F Wright; T Alp Ikizler
Journal:  Am J Nephrol       Date:  2012-08-17       Impact factor: 3.754

10.  Higher Immunological Protection of Pandemic 2009 H1N1 Influenza Live Virus Infection than Split Vaccine Against the Homologous Virus for Long Term Immunization in Ferret.

Authors:  Lingjun Zhan; Wei Deng; Linlin Bao; Qi Lv; Chunmei Ma; Fengdi Li; Lili Xu; Chuan Qin
Journal:  Indian J Virol       Date:  2012-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.